Nick Pizzie, the Chief Financial Officer of Axsome Therapeutics, Inc. (NASDAQ:AXSM), recently executed a series of stock transactions according to a Form 4 filing with the Securities and Exchange ...

Highlights,Several major investment firms have adjusted their stakes in Axsome Therapeutics, reflecting evolving market ...

Highlights,Financial institutions have adjusted their outlook on Axsome Therapeutics, revising expectations.,Institutional ...

In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research ...